Jesse J Swen

List of Publications by Year
in descending order

110 papers	4,343 citations	172207 29 h-index	123241 61 g-index
113 all docs	113 docs citations	113 times ranked	4443 citing authors

#	Article	IF	Citations
1	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clinical Pharmacology and Therapeutics, 2018, 103, 210-216.	2.3	407
2	Standardizing <scp>CYP</scp>2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. Clinical and Translational Science, 2020, 13, 116-124.	1.5	353
3	Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process. Current Drug Metabolism, 2014, 15, 209-217.	0.7	341
4	DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncology, The, 2018, 19, 1459-1467.	5.1	238
5	Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group. Clinical Pharmacology and Therapeutics, 2018, 103, 599-618.	2.3	186
6	Translating Pharmacogenomics: Challenges on the Road to the Clinic. PLoS Medicine, 2007, 4, e209.	3.9	174
7	Challenges in CYP2D6 Phenotype Assignment from Genotype Data: A Critical Assessment and Call for Standardization. Current Drug Metabolism, 2014, 15, 218-232.	0.7	147
8	Dutch Pharmacogenetics Working Group (DPWG) guideline for the geneâ€“drug interaction of DPYD and fluoropyrimidines. European Journal of Human Genetics, 2020, 28, 508-517.	1.4	127
9	Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time. European Journal of Cancer, 2016, 54, 40-48.	1.3	110
10	A Review of Mathematical Models for Tumor Dynamics and Treatment Resistance Evolution of Solid Tumors. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 720-737.	1.3	90
11	Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Therapeutic Drug Monitoring, 2021, 43, 150-200.	1.0	89
12	Phenoconversion of Cytochrome P450 Metabolism: A Systematic Review. Journal of Clinical Medicine, 2020, 9, 2890.	1.0	84
13	Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score. Pharmacogenomics, 2015, 16, 1275-1284.	0.6	81
14	CYP3A5 and ABCB1 Polymorphisms as Predictors for Sunitinib Outcome in Metastatic Renal Cell Carcinoma. European Urology, 2015, 68, 621-629.	0.9	75
15	Development of the <scp>PG</scp>xâ€Passport: A Panel of Actionable Germline Genetic Variants for Preâ€Emptive Pharmacogenetic Testing. Clinical Pharmacology and Therapeutics, 2019, 106, 866-873.	2.3	73
16	Pharmacogenetic Information in Clinical Guidelines: The European Perspective. Clinical Pharmacology and Therapeutics, 2018, 103, 795-801.	2.3	71
17	Therapeutic drug monitoring of tacrolimus and mycophenolic acid in outpatient renal transplant recipients using a volumetric dried blood spot sampling device. British Journal of Clinical Pharmacology, 2018, 84, 2889-2902.	1.1	70
18	Flexible and Scalable Full-Length CYP2D6 Long Amplicon PacBio Sequencing. Human Mutation, 2017, 38, 310-316.	1.1	69

#	Article	IF	Citations
19	Implementing pharmacogenomics decision support across seven European countries: The Ubiquitous Pharmacogenomics (U-PGx) project. Journal of the American Medical Informatics Association: JAMIA, 2018, 25, 893-898.	2.2	67
20	A cost analysis of upfront DPYD genotypeâ€“guided dose individualisation in fluoropyrimidine-based anticancer therapy. European Journal of Cancer, 2019, 107, 60-67.	1.3	65
21	Evaluation of Current Regulation and Guidelines of Pharmacogenomic Drug Labels: Opportunities for Improvements. Clinical Pharmacology and Therapeutics, 2020, 107, 1240-1255.	2.3	62
22	Pharmacist-Initiated Pre-Emptive Pharmacogenetic Panel Testing with Clinical Decision Support in Primary Care: Record of PGx Results and Real-World Impact. Genes, 2019, 10, 416.	1.0	58
23	Estimated nationwide impact of implementing a preemptive pharmacogenetic panel approach to guide drug prescribing in primary care in The Netherlands. BMC Medicine, 2019, 17, 110.	2.3	56
24	Distinct Effects of Inflammation on Cytochrome P450 Regulation and Drug Metabolism: Lessons from Experimental Models and a Potential Role for Pharmacogenetics. Genes, 2020, 11, 1509.	1.0	55
25	Toward predicting CYP2D6-mediated variable drug response from CYP2D6 gene sequencing data. Science Translational Medicine, 2021, 13, .	5.8	42
26	A nationwide survey of pharmacistsâ€™ perception of pharmacogenetics in the context of a clinical decision support system containing pharmacogenetics dosing recommendations. Pharmacogenomics, 2017, 18, 215-225.	0.6	40
27	A pilot study of the implementation of pharmacogenomic pharmacist initiated pre-emptive testing in primary care. European Journal of Human Genetics, 2019, 27, 1532-1541.	1.4	38
28	Technologies for Pharmacogenomics: A Review. Genes, 2020, 11, 1456.	1.0	37
29	Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs. European Journal of Human Genetics, 2022, 30, 1114-1120.	1.4	37
30	Implementation of Pharmacogenomics in Everyday Clinical Settings. Advances in Pharmacology, 2018, 83, 219-246.	1.2	33
31	Effect of genetic variants GSTA1 and CYP39A1 and age on busulfan clearance in pediatric patients undergoing hematopoietic stem cell transplantation. Pharmacogenomics, 2013, 14, 1683-1690.	0.6	32
32	Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study. Clinical Pharmacology and Therapeutics, 2022, 112, 62-68.	2.3	32
33	Insulin-like growth factor 1 receptor expression and IGF1R 3129Gâ€‰>â€‰T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01). Breast Cancer Research, 2016, 18, 3.	2.2	30
34	Diagnostic Test Criteria for HLA Genotyping to Prevent Drug Hypersensitivity Reactions: A Systematic Review of Actionable HLA Recommendations in CPIC and DPWG Guidelines. Frontiers in Pharmacology, 2020, 11, 567048.	1.6	28
35	Assessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysis. Acta OncolÃ³gica, 2017, 56, 582-589.	0.8	27
36	The Clinical Impact of the C0/D Ratio and the CYP3A5 Genotype on Outcome in Tacrolimus Treated Kidney Transplant Recipients. Frontiers in Pharmacology, 2020, 11, 1142.	1.6	27

#	Article	IF	Citations
37	The end of the laboratory developed test as we know it? Recommendations from a national multidisciplinary taskforce of laboratory specialists on the interpretation of the IVDR and its complications. Clinical Chemistry and Laboratory Medicine, 2021, 59, 491-497.	1.4	27
38	UGT1A1 genotype-guided dosing of irinotecan: AÂprospective safety and cost analysis in poor metaboliser patients. European Journal of Cancer, 2022, 162, 148-157.	1.3	27
39	FcGR genetic polymorphisms and the response to adalimumab in patients with rheumatoid arthritis. Pharmacogenomics, 2015, 16, 373-381.	0.6	26
40	Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study. Pharmacogenetics and Genomics, 2020, 30, 131-144.	0.7	26
41	Applying Next-Generation Sequencing Platforms for Pharmacogenomic Testing in Clinical Practice. Frontiers in Pharmacology, 2021, 12, 693453.	1.6	26
42	Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-treated patients. Pharmacogenomics, 2016, 17, 721-729.	0.6	24
43	Repurposing of Diagnostic Whole Exome Sequencing Data of 1,583 Individuals for Clinical Pharmacogenetics. Clinical Pharmacology and Therapeutics, 2020, 107, 617-627.	2.3	24
44	A brighter future for the implementation of pharmacogenomic testing. European Journal of Human Genetics, 2016, 24, 1658-1660.	1.4	23
45	Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus. Pharmacogenomics, 2010, 11, 1517-1523.	0.6	22
46	Just how feasible is pharmacogenetic testing in the primary healthcare setting?. Pharmacogenomics, 2012, 13, 507-509.	0.6	22
47	Dutch Pharmacogenetics Working Group (DPWG) guideline for the geneâ€“drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone). European Journal of Human Genetics, 2022, 30, 1105-1113.	1.4	22
48	Assessing the Implementation of Pharmacogenomic Panel-Testing in Primary Care in the Netherlands Utilizing a Theoretical Framework. Journal of Clinical Medicine, 2020, 9, 814.	1.0	20
49	Volumetric microsampling for simultaneous remote immunosuppressant and kidney function monitoring in outpatient kidney transplant recipients. British Journal of Clinical Pharmacology, 2022, 88, 4854-4869.	1.1	20
50	Pharmacogenomics decision support in the U-PGx project: Results and advice from clinical implementation across seven European countries. PLoS ONE, 2022, 17, e0268534.	1.1	20
51	Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma. European Journal of Clinical Pharmacology, 2015, 71, 1477-1484.	0.8	19
52	A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review. Expert Review of Molecular Diagnostics, 2016, 16, 605-618.	1.5	19
53	The effect of rs5758550 on CYP2D6*2 phenotype and formation of endoxifen in breast cancer patients using tamoxifen. Pharmacogenomics, 2017, 18, 1125-1132.	0.6	19
54	The Ubiquitous Pharmacogenomics consortium: making effective treatment optimization accessible to every European citizen. Pharmacogenomics, 2017, 18, 1041-1045.	0.6	19

#	Article	IF	Citations
55	Genetic risk factors for drug-induced liver injury in rheumatoid arthritis patients using low-dose methotrexate. Pharmacogenomics, 2013, 14, 63-73.	0.6	18
56	Exploratory analysis of 1936 SNPs in ADME genes for association with busulfan clearance in adult hematopoietic stem cell recipients. Pharmacogenetics and Genomics, 2013, 23, 675-683.	0.7	17
57	Application of long-read sequencing to elucidate complex pharmacogenomic regions: a proof of principle. Pharmacogenomics Journal, 2022, 22, 75-81.	0.9	17
58	Evidence synthesis and guideline development in genomic medicine: current status and future prospects. Genetics in Medicine, 2015, 17, 63-67.	1.1	16
59	A nationwide cross-sectional survey of pharmacy students on pharmacogenetic testing in The Netherlands. Pharmacogenomics, 2018, 19, 311-319.	0.6	16
60	Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers. European Journal of Cancer, 2018, 104, 210-218.	1.3	14
61	Educating the Next Generation of Pharmacogenomics Experts: Global Educational Needs and Concepts. Clinical Pharmacology and Therapeutics, 2019, 106, 313-316.	2.3	14
62	Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib. European Journal of Cancer, 2017, 86, 226-232.	1.3	13
63	Validation of a clinical pharmacogenetic model to predict methotrexate nonresponse in rheumatoid arthritis patients. Pharmacogenomics, 2019, 20, 85-93.	0.6	13
64	Model-informed precision dosing to optimise immunosuppressive therapy in renal transplantation. Drug Discovery Today, 2021, 26, 2527-2546.	3.2	12
65	Pharmacogenomic testing in paediatrics: Clinical implementation strategies. British Journal of Clinical Pharmacology, 2022, 88, 4297-4310.	1.1	12
66	Why We Need to Take a Closer Look at Genetic Contributions to CYP3A Activity. Frontiers in Pharmacology, 0, 13, .	1.6	12
67	Diagnostic and Therapeutic Strategies for Fluoropyrimidine Treatment of Patients Carrying Multiple DPYD Variants. Genes, 2018, 9, 585.	1.0	10
68	Predictive genetic biomarkers for the efficacy of methotrexate in rheumatoid arthritis: a systematic review. Pharmacogenomics Journal, 2020, 20, 159-168.	0.9	10
69	Exposureâ€“response analysis of endoxifen serum concentrations in early-breast cancer. Cancer Chemotherapy and Pharmacology, 2020, 85, 1141-1152.	1.1	10
70	GenoChip CYP2D6 macroarray as a method to genotype for CYP2D6 variants: results of a validation study in a Caucasian population. Pharmacogenomics, 2015, 16, 681-687.	0.6	9
71	Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors. Pharmacogenomics Journal, 2019, 19, 473-479.	0.9	9
72	Substrate specificity of CYP2D6 genetic variants. Pharmacogenomics, 2021, 22, 1081-1089.	0.6	9

#	Article	IF	Citations
73	Towards Fixed Dosing of Tocilizumab in ICU-Admitted COVID-19 Patients: Results of an Observational Population Pharmacokinetic and Descriptive Pharmacodynamic Study. Clinical Pharmacokinetics, 2022, 61, 231-247.	1.6	9
74	Cost-Effectiveness of Pharmacogenomics-Guided Prescribing to Prevent Gene-Drug-Related Deaths: A Decision-Analytic Model. Frontiers in Pharmacology, 0, 13, .	1.6	9
75	Using Personal Genomic Data within Primary Care: A Bioinformatics Approach to Pharmacogenomics. Genes, 2020, 11, 1443.	1.0	8
76	Population pharmacokinetics and genetics of oral meltdose tacrolimus (Envarsus) in stable adult liver transplant recipients. British Journal of Clinical Pharmacology, 2021, 87, 4262-4272.	1.1	8
77	Genetic risk factors for type 2 diabetes mellitus and response to sulfonylurea treatment. Pharmacogenetics and Genomics, 2011, 21, 461-468.	0.7	7
78	Alternative methods to a TaqMan assay to detect a tri-allelic single nucleotide polymorphism rs757210 in the HNF1Î² gene. Clinical Chemistry and Laboratory Medicine, 2012, 50, 279-84.	1.4	7
79	A Genetic Polymorphism in CTLA-4 Is Associated with Overall Survival in Sunitinib-Treated Patients with Clear Cell Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2018, 24, 2350-2356.	3.2	7
80	Pharmacogenetics of taste: turning bitter pills sweet?. Pharmacogenomics, 2014, 15, 111-119.	0.6	6
81	Pathway analysis to identify genetic variants associated with efficacy of adalimumab in rheumatoid arthritis. Pharmacogenomics, 2017, 18, 945-953.	0.6	6
82	Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing. Clinical Pharmacokinetics, 2021, 60, 89-102.	1.6	6
83	Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients. Oncotarget, 2017, 8, 1204-1212.	0.8	6
84	Abnormal Results of Newborn Screening for SCID After Azathioprine Exposure In Utero: Benefit of TPMT Genotyping in Both Mother and Child. Journal of Clinical Immunology, 2022, 42, 199-202.	2.0	6
85	SNPs and Haplotypes in DPYD and Outcome of Capecitabineâ€“Letter. Clinical Cancer Research, 2011, 17, 5833-5834.	3.2	5
86	Influence of CYP2C8 polymorphisms on imatinib steady-state trough level in chronic myeloid leukemia and gastrointestinal stromal tumor patients. Pharmacogenetics and Genomics, 2017, 27, 223-226.	0.7	5
87	Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma. Pharmacogenetics and Genomics, 2017, 27, 227-231.	0.7	5
88	Comparison of the Impact of Pharmacogenetic Variability on the PK of Slow Release and Immediate Release Tacrolimus Formulations. Genes, 2020, 11, 1205.	1.0	5
89	Model-Based Estimation of Iohexol Plasma Clearance for Pragmatic Renal Function Determination in the Renal Transplantation Setting. Clinical Pharmacokinetics, 2021, 60, 1201-1215.	1.6	5
90	Clinical validation study of genetic markers for capecitabine efficacy in metastatic colorectal cancer patients. Pharmacogenetics and Genomics, 2015, 25, 279-288.	0.7	4

#	Article	IF	Citations
91	Safety and pharmacokinetic analysis of UGT1A1 genotype-guided dosing of irinotecan.. Journal of Clinical Oncology, 2021, 39, 3574-3574.	0.8	3
92	A prospective study on the effect of endoxifen concentration and CYP2D6 phenotypes on clinical outcome in early stage breast cancer patients receiving adjuvant tamoxifen.. Journal of Clinical Oncology, 2018, 36, 523-523.	0.8	3
93	A Systematic Review on Diseaseâ€Drugâ€Drug Interactions with immunomodulating drugs: A Critical Appraisal of Risk Assessment and Drug Labelling. British Journal of Clinical Pharmacology, 2022, , .	1.1	3
94	The challenges of developing a â€˜medical-gradeâ€™ genome. Pharmacogenomics, 2012, 13, 369-372.	0.6	2
95	Pharmacogenetics in Transplant Patients: Mind the Mix. Clinical Pharmacology and Therapeutics, 2013, 94, 443-444.	2.3	2
96	Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase (DPD) splice site variant: the need for further revision of dose and schedule. Internal and Emergency Medicine, 2014, 9, 481-482.	1.0	2
97	SLC04A1, SLC22A2 and SLC28A2 variants not related to methotrexate efficacy or toxicity in rheumatoid arthritis patients. Pharmacogenomics, 2018, 19, 613-619.	0.6	2
98	Effects of age and genetic variations in VKORC1, CYP2C9 and CYP3A4 on the phenprocoumon dose in pediatric patients. Pharmacogenomics, 2018, 19, 1195-1202.	0.6	2
99	Pharmacogenomics Education and Clinical Practice Guidelines. , 2019, , 395-414.		2
100	Confirmation practice in pharmacogenetic testing; how good is good enough?. Clinica Chimica Acta, 2019, 490, 77-80.	0.5	2
101	What do we need to make genetic biomarker-guided treatment for renal cell carcinoma a reality?. Pharmacogenomics, 2017, 18, 1-4.	0.6	1
102	One nonâ€believer: Response to â€œObviously Nine Believers: Actionable Germline Genetic Variants for Preâ€emptive Pharmacogenetic Testingâ€. Basic and Clinical Pharmacology and Toxicology, 2020, 126, 7-8.	1.2	1
103	Precision Medicine Using Pharmacogenomic Panel-Testing. Advances in Molecular Pathology, 2020, 3, 131-142.	0.2	1
104	Pharmacogenomic Determinants of Interindividual Drug Response Variability: From Discovery to Implementation. Genes, 2021, 12, 393.	1.0	1
105	Genome-Wide Meta-Analysis Identifies Variants in DSCAM and PDLIM3 That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib. Cancers, 2022, 14, 2838.	1.7	1
106	Comment: Global Formulary Review: How Do We Integrate Pharmacogenomic Information?. Annals of Pharmacotherapy, 2011, 45, 1030-1030.	0.9	0
107	Centres of Excellence Course in Pharmacogenetics, 25â€“28 June 2012. European Journal of Hospital Pharmacy, 2013, 20, 132-132.	0.5	0
108	Farmacogenetica in uw spreekkamer. Bijblijven (Amsterdam, Netherlands), 2015, 31, 578-588.	0.0	0

#	Article	IF	Citations
109	Association analysis of polymorphisms in genes related to sunitinib pharmacokinetics.. Journal of Clinical Oncology, 2013, 31, 4580-4580.	0.8	0
110	CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2015, 33, 4548-4548.	0.8	0